{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:02:10Z","timestamp":1789459330290,"version":"build-2803163510"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"International Cooperation Projects of the Science and Technology Department of Sichuan Province","award":["2026YFHZ0053"],"award-info":[{"award-number":["2026YFHZ0053"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08945-x","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:15:02Z","timestamp":1789121702000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Secreted protein circuits in the gastrointestinal tumour microenvironment: determinants of immunotherapy response and resistance"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7953-1805","authenticated-orcid":false,"given":"Kexun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilong","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongtao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"8945_CR1","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature12626","volume":"501","author":"MR Junttila","year":"2013","unstructured":"Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501:346\u201354. https:\/\/doi.org\/10.1038\/nature12626.","journal-title":"Nature"},{"key":"8945_CR2","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri.2017.49","volume":"17","author":"N Nagarsheth","year":"2017","unstructured":"Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17:559\u201372. https:\/\/doi.org\/10.1038\/nri.2017.49.","journal-title":"Nat Rev Immunol"},{"key":"8945_CR3","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541\u201350. https:\/\/doi.org\/10.1038\/s41591-018-0014-x.","journal-title":"Nat Med"},{"key":"8945_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012.","journal-title":"Immunity"},{"key":"8945_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1059.","journal-title":"Cancer Discov"},{"key":"8945_CR6","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nri3896","volume":"15","author":"NR West","year":"2015","unstructured":"West NR, McCuaig S, Franchini F, Powrie F. Emerging cytokine networks in colorectal cancer. Nat Rev Immunol. 2015;15:615\u201329. https:\/\/doi.org\/10.1038\/nri3896.","journal-title":"Nat Rev Immunol"},{"key":"8945_CR7","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","volume":"38","author":"AS Bear","year":"2020","unstructured":"Bear AS, Vonderheide RH, O\u2019Hara MH. Challenges and opportunities for pancreatic cancer immunotherapy. Cancer Cell. 2020;38:788\u2013802. https:\/\/doi.org\/10.1016\/j.ccell.2020.08.004.","journal-title":"Cancer Cell"},{"key":"8945_CR8","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41590-018-0044-z","volume":"19","author":"M Ringelhan","year":"2018","unstructured":"Ringelhan M, Pfister D, O\u2019Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19:222\u201332. https:\/\/doi.org\/10.1038\/s41590-018-0044-z.","journal-title":"Nat Immunol"},{"key":"8945_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19:151\u201372. https:\/\/doi.org\/10.1038\/s41571-021-00573-2.","journal-title":"Nat Rev Clin Oncol"},{"key":"8945_CR10","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.ccell.2015.02.015","volume":"27","author":"B Ruffell","year":"2015","unstructured":"Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015;27:462\u201372. https:\/\/doi.org\/10.1016\/j.ccell.2015.02.015.","journal-title":"Cancer Cell"},{"key":"8945_CR11","doi-asserted-by":"publisher","first-page":"717850","DOI":"10.3389\/fimmu.2021.717850","volume":"12","author":"M Etxebeste-Mitxeltorena","year":"2021","unstructured":"Etxebeste-Mitxeltorena M, del Rinc\u00f3n-Loza I, Mart\u00edn-Antonio B. Tumor secretome to adoptive cellular immunotherapy: reduce me before I make you my partner. Front Immunol. 2021;12:717850. https:\/\/doi.org\/10.3389\/fimmu.2021.717850.","journal-title":"Front Immunol"},{"key":"8945_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet"},{"issue":"6","key":"8945_CR13","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.annonc.2026.02.003","volume":"37","author":"YY Janjigian","year":"2026","unstructured":"Janjigian YY, Shitara K, Ajani JA, et al. Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649. Ann Oncol. 2026;37(6):787\u201397. https:\/\/doi.org\/10.1016\/j.annonc.2026.02.003.","journal-title":"Ann Oncol"},{"key":"8945_CR14","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1181\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(23)00515-6.","journal-title":"Lancet Oncol"},{"key":"8945_CR15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386:449\u201362. https:\/\/doi.org\/10.1056\/NEJMoa2111380.","journal-title":"N Engl J Med"},{"key":"8945_CR16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398:759\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(21)01234-4.","journal-title":"Lancet"},{"key":"8945_CR17","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207\u201318. https:\/\/doi.org\/10.1056\/NEJMoa2017699.","journal-title":"N Engl J Med"},{"key":"8945_CR18","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, et al. PD-1 blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372:2509\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1500596.","journal-title":"N Engl J Med"},{"key":"8945_CR19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409\u201313. https:\/\/doi.org\/10.1126\/science.aan6733.","journal-title":"Science"},{"key":"8945_CR20","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022;386:2363\u201376. https:\/\/doi.org\/10.1056\/NEJMoa2201445.","journal-title":"N Engl J Med"},{"key":"8945_CR21","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","volume":"391","author":"T Andr\u00e9","year":"2024","unstructured":"Andr\u00e9 T, Elez E, Van Cutsem E, et al. Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer. N Engl J Med. 2024;391:2014\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2402141.","journal-title":"N Engl J Med"},{"key":"8945_CR22","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","volume":"405","author":"T Andr\u00e9","year":"2025","unstructured":"Andr\u00e9 T, Elez E, Lenz HJ, et al. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. Lancet. 2025;405:383\u201395. https:\/\/doi.org\/10.1016\/S0140-6736(24)02848-4.","journal-title":"Lancet"},{"key":"8945_CR23","unstructured":"U.S. Food and Drug Administration. FDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer. Published 8 April 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer. Accessed 23 May 2026."},{"key":"8945_CR24","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905. https:\/\/doi.org\/10.1056\/NEJMoa1915745.","journal-title":"N Engl J Med"},{"key":"8945_CR25","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862\u201373. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.030.","journal-title":"J Hepatol"},{"key":"8945_CR26","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1:EVIDoa2100070. https:\/\/doi.org\/10.1056\/EVIDoa2100070.","journal-title":"NEJM Evid"},{"key":"8945_CR27","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1:EVIDoa2200015. https:\/\/doi.org\/10.1056\/EVIDoa2200015.","journal-title":"NEJM Evid"},{"key":"8945_CR28","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab plus gemcitabine and cisplatin in advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1853\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4.","journal-title":"Lancet"},{"key":"8945_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","volume":"63","author":"R Tokunaga","year":"2018","unstructured":"Tokunaga R, Zhang W, Naseem M, et al. CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - A target for novel cancer therapy. Cancer Treat Rev. 2018;63:40\u20137. https:\/\/doi.org\/10.1016\/j.ctrv.2017.11.007.","journal-title":"Cancer Treat Rev"},{"key":"8945_CR30","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1158\/2326-6066.CIR-14-0160","volume":"2","author":"MT Chow","year":"2014","unstructured":"Chow MT, Luster AD. Chemokines in cancer. Cancer Immunol Res. 2014;2:1125\u201331. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0160.","journal-title":"Cancer Immunol Res"},{"key":"8945_CR31","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita R, Lauss M, Sanna A, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577:561\u20135. https:\/\/doi.org\/10.1038\/s41586-019-1914-8.","journal-title":"Nature"},{"key":"8945_CR32","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink BA, Reddy SM, Gao J, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577:549\u201355. https:\/\/doi.org\/10.1038\/s41586-019-1922-8.","journal-title":"Nature"},{"key":"8945_CR33","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/s43018-022-00433-7","volume":"3","author":"B Liu","year":"2022","unstructured":"Liu B, Zhang Y, Wang D, Hu X, Zhang Z. Single-cell meta-analyses reveal responses of tumor-reactive CXCL13 + T cells to immune-checkpoint blockade. Nat Cancer. 2022;3:1123\u201336. https:\/\/doi.org\/10.1038\/s43018-022-00433-7.","journal-title":"Nat Cancer"},{"key":"8945_CR34","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, et al. TGF-\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544\u20138. https:\/\/doi.org\/10.1038\/nature25501.","journal-title":"Nature"},{"key":"8945_CR35","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature25492","volume":"554","author":"DVF Tauriello","year":"2018","unstructured":"Tauriello DVF, Palomo-Ponce S, Stork D, et al. TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554:538\u201343. https:\/\/doi.org\/10.1038\/nature25492.","journal-title":"Nature"},{"key":"8945_CR36","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle E, Massagu\u00e9 J. Transforming Growth Factor-\u03b2 Signaling in Immunity and Cancer. Immunity. 2019;50:924\u201340. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.024.","journal-title":"Immunity"},{"key":"8945_CR37","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.20140559","volume":"212","author":"T Voron","year":"2015","unstructured":"Voron T, Colussi O, Marcheteau E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8 + T cells in tumors. J Exp Med. 2015;212:139\u201348. https:\/\/doi.org\/10.1084\/jem.20140559.","journal-title":"J Exp Med"},{"key":"8945_CR38","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nri3064","volume":"11","author":"GT Motz","year":"2011","unstructured":"Motz GT, Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol. 2011;11:702\u201311. https:\/\/doi.org\/10.1038\/nri3064.","journal-title":"Nat Rev Immunol"},{"key":"8945_CR39","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15:325\u201340. https:\/\/doi.org\/10.1038\/nrclinonc.2018.29.","journal-title":"Nat Rev Clin Oncol"},{"key":"8945_CR40","doi-asserted-by":"publisher","first-page":"eaay0555","DOI":"10.1126\/sciimmunol.aay0555","volume":"4","author":"CG Kim","year":"2019","unstructured":"Kim CG, Jang M, Kim Y, et al. VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers. Sci Immunol. 2019;4:eaay0555. https:\/\/doi.org\/10.1126\/sciimmunol.aay0555.","journal-title":"Sci Immunol"},{"key":"8945_CR41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.semcancer.2017.12.002","volume":"52","author":"PS Hegde","year":"2018","unstructured":"Hegde PS, Wallin JJ, Mancao C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol. 2018;52:117\u201324. https:\/\/doi.org\/10.1016\/j.semcancer.2017.12.002.","journal-title":"Semin Cancer Biol"},{"key":"8945_CR42","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig C, Jones JO, Kraman M, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013;110:20212\u20137. https:\/\/doi.org\/10.1073\/pnas.1320318110.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8945_CR43","doi-asserted-by":"publisher","first-page":"28960","DOI":"10.1073\/pnas.2013644117","volume":"117","author":"D Biasci","year":"2020","unstructured":"Biasci D, Smoragiewicz M, Connell CM, et al. CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response. Proc Natl Acad Sci U S A. 2020;117:28960\u201370. https:\/\/doi.org\/10.1073\/pnas.2013644117.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8945_CR44","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","volume":"26","author":"B Bockorny","year":"2020","unstructured":"Bockorny B, Semenisty V, Macarulla T, et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med. 2020;26:878\u201385. https:\/\/doi.org\/10.1038\/s41591-020-0880-x.","journal-title":"Nat Med"},{"key":"8945_CR45","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.ccell.2016.04.014","volume":"29","author":"CW Steele","year":"2016","unstructured":"Steele CW, Karim SA, Leach JDG, et al. CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell. 2016;29:832\u201345. https:\/\/doi.org\/10.1016\/j.ccell.2016.04.014.","journal-title":"Cancer Cell"},{"key":"8945_CR46","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1093\/annonc\/mdx190","volume":"28","author":"MF Sanmamed","year":"2017","unstructured":"Sanmamed MF, Perez-Gracia JL, Schalper KA, et al. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Ann Oncol. 2017;28:1988\u201395. https:\/\/doi.org\/10.1093\/annonc\/mdx190.","journal-title":"Ann Oncol"},{"key":"8945_CR47","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","volume":"26","author":"KA Schalper","year":"2020","unstructured":"Schalper KA, Carleton M, Zhou M, et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat Med. 2020;26:688\u201392. https:\/\/doi.org\/10.1038\/s41591-020-0856-x.","journal-title":"Nat Med"},{"key":"8945_CR48","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","volume":"17","author":"TM Nywening","year":"2016","unstructured":"Nywening TM, Wang-Gillam A, Sanford DE, et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016;17:651\u201362. https:\/\/doi.org\/10.1016\/S1470-2045(16)00078-4.","journal-title":"Lancet Oncol"},{"key":"8945_CR49","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","volume":"74","author":"Y Zhu","year":"2014","unstructured":"Zhu Y, Knolhoff BL, Meyer MA, et al. CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74:5057\u201369. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-3723.","journal-title":"Cancer Res"},{"issue":"5","key":"8945_CR50","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.celrep.2018.03.131","volume":"23","author":"JB Candido","year":"2018","unstructured":"Candido JB, Morton JP, Bailey P, et al. CSF1R+ macrophages sustain pancreatic tumor growth through T cell suppression and maintenance of key gene programs that define the squamous subtype. Cell Rep. 2018;23(5):1448\u201360. https:\/\/doi.org\/10.1016\/j.celrep.2018.03.131.","journal-title":"Cell Rep"},{"key":"8945_CR51","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1136\/gutjnl-2016-311585","volume":"67","author":"TA Mace","year":"2018","unstructured":"Mace TA, Shakya R, Pitarresi JR, et al. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut. 2018;67:320\u201332. https:\/\/doi.org\/10.1136\/gutjnl-2016-311585.","journal-title":"Gut"},{"key":"8945_CR52","doi-asserted-by":"publisher","first-page":"149185","DOI":"10.1155\/2014\/149185","volume":"2014","author":"G Landskron","year":"2014","unstructured":"Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic Inflammation and Cytokines in the Tumor Microenvironment. J Immunol Res. 2014;2014:149185. https:\/\/doi.org\/10.1155\/2014\/149185.","journal-title":"J Immunol Res"},{"key":"8945_CR53","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nature04808","volume":"442","author":"JL Langowski","year":"2006","unstructured":"Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumour incidence and growth. Nature. 2006;442:461\u20135. https:\/\/doi.org\/10.1038\/nature04808.","journal-title":"Nature"},{"key":"8945_CR54","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1084\/jem.20090207","volume":"206","author":"L Wang","year":"2009","unstructured":"Wang L, Yi T, Kortylewski M, et al. IL-17 can promote tumor growth through an IL-6\u2013Stat3 signaling pathway. J Exp Med. 2009;206:1457\u201364. https:\/\/doi.org\/10.1084\/jem.20090207.","journal-title":"J Exp Med"},{"key":"8945_CR55","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.1016\/j.cell.2021.08.003","volume":"184","author":"K Pelka","year":"2021","unstructured":"Pelka K, Hofree M, Chen JH, et al. Spatially organized multicellular immune hubs in human colorectal cancer. Cell. 2021;184:4734\u2013e475220. https:\/\/doi.org\/10.1016\/j.cell.2021.08.003.","journal-title":"Cell"},{"key":"8945_CR56","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/s41467-022-29366-6","volume":"13","author":"J Qi","year":"2022","unstructured":"Qi J, Sun H, Zhang Y, et al. Single-cell and spatial analysis reveal interaction of FAP+ fibroblasts and SPP1 + macrophages in colorectal cancer. Nat Commun. 2022;13:1742. https:\/\/doi.org\/10.1038\/s41467-022-29366-6.","journal-title":"Nat Commun"},{"key":"8945_CR57","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41419-018-0391-6","volume":"9","author":"H Zhao","year":"2018","unstructured":"Zhao H, Chen Q, Alam A, et al. The role of osteopontin in the progression of solid organ tumour. Cell Death Dis. 2018;9:356. https:\/\/doi.org\/10.1038\/s41419-018-0391-6.","journal-title":"Cell Death Dis"},{"key":"8945_CR58","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12967-023-04688-1","volume":"22","author":"Y Du","year":"2024","unstructured":"Du Y, Lin Y, Gan L, et al. Potential crosstalk between SPP1 + TAMs and CD8 + exhausted T cells promotes an immunosuppressive environment in gastric metastatic cancer. J Transl Med. 2024;22:158. https:\/\/doi.org\/10.1186\/s12967-023-04688-1.","journal-title":"J Transl Med"},{"key":"8945_CR59","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.3390\/cancers13051006","volume":"13","author":"JD Klement","year":"2021","unstructured":"Klement JD, Poschel DB, Lu C, et al. Osteopontin blockade immunotherapy increases cytotoxic T lymphocyte lytic activity and suppresses colon tumor progression. Cancers (Basel). 2021;13:1006. https:\/\/doi.org\/10.3390\/cancers13051006.","journal-title":"Cancers (Basel)"},{"key":"8945_CR60","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.ajpath.2013.11.012","volume":"184","author":"Y Kikuchi","year":"2014","unstructured":"Kikuchi Y, Kunita A, Iwata C, et al. The niche component periostin is produced by cancer-associated fibroblasts, supporting growth of gastric cancer through ERK activation. Am J Pathol. 2014;184:859\u201370. https:\/\/doi.org\/10.1016\/j.ajpath.2013.11.012.","journal-title":"Am J Pathol"},{"key":"8945_CR61","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.celrep.2019.12.075","volume":"30","author":"H Ma","year":"2020","unstructured":"Ma H, Wang J, Zhao X, et al. Periostin promotes colorectal tumorigenesis through integrin-FAK-Src pathway-mediated YAP\/TAZ activation. Cell Rep. 2020;30:793\u2013e8066. https:\/\/doi.org\/10.1016\/j.celrep.2019.12.075.","journal-title":"Cell Rep"},{"key":"8945_CR62","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.cell.2014.01.043","volume":"156","author":"DO Croci","year":"2014","unstructured":"Croci DO, Cerliani JP, Dalotto-Moreno T, et al. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell. 2014;156:744\u201358. https:\/\/doi.org\/10.1016\/j.cell.2014.01.043.","journal-title":"Cell"},{"issue":"6","key":"8945_CR63","doi-asserted-by":"publisher","first-page":"e1434467","DOI":"10.1080\/2162402X.2018.1434467","volume":"7","author":"M Farhad","year":"2018","unstructured":"Farhad M, Rolig AS, Redmond WL. The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment. OncoImmunology. 2018;7(6):e1434467. https:\/\/doi.org\/10.1080\/2162402X.2018.1434467.","journal-title":"OncoImmunology"},{"key":"8945_CR64","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","volume":"141","author":"K Kessenbrock","year":"2010","unstructured":"Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52\u201367. https:\/\/doi.org\/10.1016\/j.cell.2010.03.015.","journal-title":"Cell"},{"key":"8945_CR65","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","volume":"9","author":"M Ruiz de Galarreta","year":"2019","unstructured":"Ruiz de Galarreta M, Bresnahan E, Molina-S\u00e1nchez P, et al. \u03b2-Catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 2019;9:1124\u201341. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0074.","journal-title":"Cancer Discov"},{"key":"8945_CR66","doi-asserted-by":"publisher","first-page":"e001498","DOI":"10.1136\/jitc-2020-001498","volume":"9","author":"Q Sui","year":"2021","unstructured":"Sui Q, Liu D, Jiang W, et al. Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8 + T cells in deficient mismatch repair colorectal cancer. J Immunother Cancer. 2021;9:e001498. https:\/\/doi.org\/10.1136\/jitc-2020-001498.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"8945_CR67","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1200\/JCO-24-01619","volume":"43","author":"T Shi","year":"2025","unstructured":"Shi T, Wei J. Targeting DKK1 to remodel the tumor microenvironment and enhance immune checkpoint blockade therapy. J Clin Oncol. 2025;43(3):350\u20133. https:\/\/doi.org\/10.1200\/JCO-24-01619.","journal-title":"J Clin Oncol"},{"key":"8945_CR68","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s12253-016-0138-6","volume":"23","author":"CCG Nobre","year":"2017","unstructured":"Nobre CCG, de Ara\u00fajo JMG, Fernandes TAAM, et al. Macrophage migration inhibitory factor (MIF): biological activities and relation with cancer. Pathol Oncol Res. 2017;23:235\u201344. https:\/\/doi.org\/10.1007\/s12253-016-0138-6.","journal-title":"Pathol Oncol Res"},{"key":"8945_CR69","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.cytogfr.2015.03.002","volume":"26","author":"AN Gordon-Weeks","year":"2015","unstructured":"Gordon-Weeks AN, Lim SY, Yuzhalin AE, Jones K, Muschel R. Macrophage migration inhibitory factor: a key cytokine and therapeutic target in colon cancer. Cytokine Growth Factor Rev. 2015;26:451\u201361. https:\/\/doi.org\/10.1016\/j.cytogfr.2015.03.002.","journal-title":"Cytokine Growth Factor Rev"},{"key":"8945_CR70","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/ni.1655","volume":"9","author":"MM Markiewski","year":"2008","unstructured":"Markiewski MM, DeAngelis RA, Benencia F, et al. Modulation of the antitumor immune response by complement. Nat Immunol. 2008;9:1225\u201335. https:\/\/doi.org\/10.1038\/ni.1655.","journal-title":"Nat Immunol"},{"key":"8945_CR71","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","volume":"560","author":"G Chen","year":"2018","unstructured":"Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560:382\u20136. https:\/\/doi.org\/10.1038\/s41586-018-0392-8.","journal-title":"Nature"},{"key":"8945_CR72","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cell.2019.02.016","volume":"177","author":"M Poggio","year":"2019","unstructured":"Poggio M, Hu T, Pai CC, et al. Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. Cell. 2019;177:414\u2013e42713. https:\/\/doi.org\/10.1016\/j.cell.2019.02.016.","journal-title":"Cell"},{"key":"8945_CR73","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1158\/2326-6066.CIR-16-0329","volume":"5","author":"J Zhou","year":"2017","unstructured":"Zhou J, Mahoney KM, Giobbie-Hurder A, et al. Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade. Cancer Immunol Res. 2017;5:480\u201392. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0329.","journal-title":"Cancer Immunol Res"},{"key":"8945_CR74","doi-asserted-by":"publisher","first-page":"112437","DOI":"10.1016\/j.celrep.2023.112437","volume":"42","author":"Q Luo","year":"2023","unstructured":"Luo Q, Dong Z, Xie W, et al. Apatinib remodels the immunosuppressive tumor ecosystem of gastric cancer enhancing anti-PD-1 immunotherapy. Cell Rep. 2023;42:112437. https:\/\/doi.org\/10.1016\/j.celrep.2023.112437.","journal-title":"Cell Rep"},{"key":"8945_CR75","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41419-025-07385-7","volume":"16","author":"D Luo","year":"2025","unstructured":"Luo D, Zhou J, Ruan S, et al. Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies. Cell Death Dis. 2025;16:75. https:\/\/doi.org\/10.1038\/s41419-025-07385-7.","journal-title":"Cell Death Dis"},{"issue":"4","key":"8945_CR76","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S1470-2045(23)00060-8","volume":"24","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Wen J, Li Q, et al. Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial. Lancet Oncol. 2023;24(4):371\u201382. https:\/\/doi.org\/10.1016\/S1470-2045(23)00060-8.","journal-title":"Lancet Oncol"},{"key":"8945_CR77","doi-asserted-by":"publisher","first-page":"9097","DOI":"10.1038\/s41467-024-52977-0","volume":"15","author":"Z Yang","year":"2024","unstructured":"Yang Z, Tian H, Chen X, et al. Single-cell sequencing reveals immune features of treatment response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma. Nat Commun. 2024;15:9097. https:\/\/doi.org\/10.1038\/s41467-024-52977-0.","journal-title":"Nat Commun"},{"key":"8945_CR78","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev A, Kotlov N, Nomie K, et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell. 2021;39:845\u2013e8657. https:\/\/doi.org\/10.1016\/j.ccell.2021.04.014.","journal-title":"Cancer Cell"},{"key":"8945_CR79","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.1158\/1078-0432.CCR-15-2879","volume":"22","author":"E Becht","year":"2016","unstructured":"Becht E, de Reyni\u00e8s A, Giraldo NA, et al. Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy. Clin Cancer Res. 2016;22:4057\u201366. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2879.","journal-title":"Clin Cancer Res"},{"key":"8945_CR80","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960\u20134. https:\/\/doi.org\/10.1126\/science.1129139.","journal-title":"Science"},{"key":"8945_CR81","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","volume":"391","author":"F Pag\u00e8s","year":"2018","unstructured":"Pag\u00e8s F, Mlecnik B, Marliot F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391:2128\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(18)30789-X.","journal-title":"Lancet"},{"key":"8945_CR82","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","volume":"17","author":"WJ Ho","year":"2020","unstructured":"Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer \u2014 clinical challenges and opportunities. Nat Rev Clin Oncol. 2020;17:527\u201340. https:\/\/doi.org\/10.1038\/s41571-020-0363-5.","journal-title":"Nat Rev Clin Oncol"},{"key":"8945_CR83","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrd.2018.169","volume":"17","author":"L Cassetta","year":"2018","unstructured":"Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 2018;17:887\u2013904. https:\/\/doi.org\/10.1038\/nrd.2018.169.","journal-title":"Nat Rev Drug Discov"},{"key":"8945_CR84","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cell.2017.05.035","volume":"169","author":"C Zheng","year":"2017","unstructured":"Zheng C, Zheng L, Yoo JK, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell. 2017;169:1342\u2013e135616. https:\/\/doi.org\/10.1016\/j.cell.2017.05.035.","journal-title":"Cell"},{"key":"8945_CR85","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1002\/hep.29904","volume":"68","author":"Y Kurebayashi","year":"2018","unstructured":"Kurebayashi Y, Ojima H, Tsujikawa H, et al. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatology. 2018;68:1025\u201341. https:\/\/doi.org\/10.1002\/hep.29904.","journal-title":"Hepatology"},{"key":"8945_CR86","doi-asserted-by":"publisher","first-page":"1166497","DOI":"10.3389\/fimmu.2023.1166497","volume":"14","author":"T Shang","year":"2023","unstructured":"Shang T, Jiang T, Lu T, et al. Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma. Front Immunol. 2023;14:1166497. https:\/\/doi.org\/10.3389\/fimmu.2023.1166497.","journal-title":"Front Immunol"},{"key":"8945_CR87","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1038\/s41467-022-29164-0","volume":"13","author":"G Song","year":"2022","unstructured":"Song G, Shi Y, Meng L, et al. Single-cell transcriptomic analysis suggests two molecularly distinct subtypes of intrahepatic cholangiocarcinoma. Nat Commun. 2022;13:1642. https:\/\/doi.org\/10.1038\/s41467-022-29164-0.","journal-title":"Nat Commun"},{"issue":"5","key":"8945_CR88","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/HEP.0000000000001423","volume":"83","author":"F Li","year":"2026","unstructured":"Li F, Li Y, Wang L, et al. Tumor microenvironment heterogeneity and progression mechanisms in intrahepatic cholangiocarcinoma: A study based on single-cell and spatial transcriptomic sequencing. Hepatology. 2026;83(5):1082\u201397. https:\/\/doi.org\/10.1097\/HEP.0000000000001423.","journal-title":"Hepatology"},{"issue":"1","key":"8945_CR89","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/HEP.0000000000001283","volume":"83","author":"L Hong","year":"2026","unstructured":"Hong L, Mei J, Sun X, et al. Spatial single-cell proteomics landscape decodes the tumor microenvironmental ecosystem of intrahepatic cholangiocarcinoma. Hepatology. 2026;83(1):57\u201374. https:\/\/doi.org\/10.1097\/HEP.0000000000001283.","journal-title":"Hepatology"},{"issue":"6","key":"8945_CR90","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/bjc.1998.158","volume":"77","author":"RE Banks","year":"1998","unstructured":"Banks RE, Forbes MA, Kinsey SE, et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer. 1998;77(6):956\u201364. https:\/\/doi.org\/10.1038\/bjc.1998.158.","journal-title":"Br J Cancer"},{"issue":"3","key":"8945_CR91","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1006\/cyto.2001.0895","volume":"16","author":"JH Jeon","year":"2001","unstructured":"Jeon JH, Kim YS, Choi EJ, et al. Implication of co-measured platelet factor 4 in the reliability of the results of the plasma transforming growth factor-\u03b21 measurement. Cytokine. 2001;16(3):102\u20135. https:\/\/doi.org\/10.1006\/cyto.2001.0895.","journal-title":"Cytokine"},{"key":"8945_CR92","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41392-022-00960-w","volume":"7","author":"L Zhang","year":"2022","unstructured":"Zhang L, Chen D, Song D, et al. Clinical and translational values of spatial transcriptomics. Signal Transduct Target Ther. 2022;7:111. https:\/\/doi.org\/10.1038\/s41392-022-00960-w.","journal-title":"Signal Transduct Target Ther"},{"key":"8945_CR93","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1038\/s41587-023-01676-0","volume":"41","author":"Y Liu","year":"2023","unstructured":"Liu Y, DiStasio M, Su G, et al. High-plex protein and whole transcriptome co-mapping at cellular resolution with spatial CITE-seq. Nat Biotechnol. 2023;41:1405\u20139. https:\/\/doi.org\/10.1038\/s41587-023-01676-0.","journal-title":"Nat Biotechnol"},{"key":"8945_CR94","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41586-025-09663-y","volume":"647","author":"D Zhang","year":"2025","unstructured":"Zhang D, Rubio Rodr\u00edguez-Kirby LA, Lin Y, et al. Spatial dynamics of brain development and neuroinflammation. Nature. 2025;647:213\u201327. https:\/\/doi.org\/10.1038\/s41586-025-09663-y.","journal-title":"Nature"},{"key":"8945_CR95","doi-asserted-by":"publisher","unstructured":"Baysoy A, Tian X, Renauer P, et al. Large-scale, spatially resolved panoramic CRISPR screening in native tissue environments using Perturb-DBiT. Nat Biotechnol Published online June. 2026;11. https:\/\/doi.org\/10.1038\/s41587-026-03127-y.","DOI":"10.1038\/s41587-026-03127-y"},{"issue":"3","key":"8945_CR96","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1097\/HEP.0000000000000965","volume":"81","author":"DY Oh","year":"2025","unstructured":"Oh DY, Ikeda M, Lee CK, et al. Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2\/3 trial. Hepatology. 2025;81(3):823\u201336. https:\/\/doi.org\/10.1097\/HEP.0000000000000965.","journal-title":"Hepatology"},{"issue":"27","key":"8945_CR97","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1200\/JCO.20.00590","volume":"38","author":"E Van Cutsem","year":"2020","unstructured":"Van Cutsem E, Tempero MA, Sigal D, et al. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. J Clin Oncol. 2020;38(27):3185\u201394. https:\/\/doi.org\/10.1200\/JCO.20.00590.","journal-title":"J Clin Oncol"},{"issue":"3","key":"8945_CR98","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s10637-019-00830-3","volume":"38","author":"M Noel","year":"2020","unstructured":"Noel M, O\u2019Reilly EM, Wolpin BM, et al. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel\/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. Invest New Drugs. 2020;38(3):800\u201311. https:\/\/doi.org\/10.1007\/s10637-019-00830-3.","journal-title":"Invest New Drugs"},{"key":"8945_CR99","unstructured":"ClinicalTrials.gov. A study of cabiralizumab given with nivolumab with and without chemotherapy in patients with advanced pancreatic cancer (NCT03336216). Updated 23 July 2024. Accessed 15 August 2026. https:\/\/clinicaltrials.gov\/study\/NCT03336216"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08945-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08945-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08945-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:02:26Z","timestamp":1789455746000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08945-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8945"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08945-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"23 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors consent to publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Author information","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not commissioned, externally peer-reviewed.","order":4,"name":"Ethics","label":"Provenance and peer review","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During preparation of this work, the authors used the AI language model ChatGPT solely to improve sentence structure and language clarity during manuscript drafting and revision. All AI-assisted text was reviewed, verified and edited by the authors, who take full responsibility for the accuracy, integrity and final content of the manuscript.","order":5,"name":"Ethics","label":"Purpose and Scope of AI Use","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":6,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1185"}}